Contrasting Regenicin (OTCMKTS:RGIN) & Inspire Medical Systems (NYSE:INSP)

Regenicin (OTCMKTS:RGIN) and Inspire Medical Systems (NYSE:INSP) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Regenicin and Inspire Medical Systems, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regenicin	0	0	0	0	0.00
Inspire Medical Systems	0	4	8	0	2.67

Inspire Medical Systems has a consensus target price of $227.75, suggesting a potential upside of 31.70%. Given Inspire Medical Systems’ stronger consensus rating and higher possible upside, analysts plainly believe Inspire Medical Systems is more favorable than Regenicin.

Risk & Volatility

Regenicin has a beta of -18.99, meaning that its stock price is 1,999% less volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500.

Institutional and Insider Ownership

0.0% of Regenicin shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 4.1% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Regenicin and Inspire Medical Systems”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A
Inspire Medical Systems	$755.59 million	6.86	-$21.15 million	$1.07	161.62

Regenicin has higher earnings, but lower revenue than Inspire Medical Systems.

Profitability

This table compares Regenicin and Inspire Medical Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Regenicin	N/A	N/A	N/A
Inspire Medical Systems	4.37%	5.30%	4.58%

Summary

Inspire Medical Systems beats Regenicin on 10 of the 11 factors compared between the two stocks.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.

About Inspire Medical Systems

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.